Claritas Pharmaceuticals, Inc. (CLAZF)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Dec 16, 2025
Claritas Pharmaceuticals Statistics
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
CLAZF has 37.79 million shares outstanding.
| Current Share Class | 37.79M |
| Shares Outstanding | 37.79M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +6.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 0.00.
| PE Ratio | 0.00 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.42, with a Debt / Equity ratio of 0.16.
| Current Ratio | 1.42 |
| Quick Ratio | 0.01 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0.17 |
Financial Efficiency
Return on equity (ROE) is 65.09% and return on invested capital (ROIC) is 14.18%.
| Return on Equity (ROE) | 65.09% |
| Return on Assets (ROA) | 2.77% |
| Return on Invested Capital (ROIC) | 14.18% |
| Return on Capital Employed (ROCE) | 14.74% |
| Weighted Average Cost of Capital (WACC) | 430.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.88M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 41.03 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | 0.04 |
| Relative Strength Index (RSI) | 45.58 |
| Average Volume (20 Days) | 2,344 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 35.48 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | 485,000 |
| Pretax Income | -3.08M |
| Net Income | -4.72M |
| EBITDA | n/a |
| EBIT | 485,000 |
| Earnings Per Share (EPS) | -0.13 |
Balance Sheet
The company has 2,000 in cash and 538,000 in debt, with a net cash position of -536,000 or -0.01 per share.
| Cash & Cash Equivalents | 2,000 |
| Total Debt | 538,000 |
| Net Cash | -536,000 |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | 3.28M |
| Book Value Per Share | 0.09 |
| Working Capital | 3.28M |
Cash Flow
| Operating Cash Flow | -953,000 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLAZF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.44% |
| Shareholder Yield | -33.44% |
| Earnings Yield | -12,415,789.47% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 23, 2021. It was a reverse split with a ratio of 0.05.
| Last Split Date | Jul 23, 2021 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |